Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592248 | 0.88 | OPRD1 (0.55) | HSD11B1APPMAPTTSHRLMNA | |
| SCHEMBL5361656 | 0.86 | HSD11B1 (0.58) | HSD11B1OPRD1OPRK1L3MBTL1 | |
| SCHEMBL21581202 | 0.84 | OPRD1 (0.63) | APPMAPTTSHROPRD1OPRK1 | |
| SCHEMBL2270783 | 0.83 | TACR1 (0.61) | HSD11B1TSHROPRD1OPRK1 | |
| SCHEMBL2425376 | 0.82 | HSD11B1 (0.58) | HSD11B1OPRM1 | |
| SCHEMBL22874143 | 0.81 | APP (0.56) | APPMAPTTSHROPRD1OPRK1 | |
| SCHEMBL13059778 | 0.80 | MEN1 (0.56) | APPOPRD1OPRK1OPRM1L3MBTL1 | |
| SCHEMBL20004189 | 0.79 | APP (0.54) | APPMAPTTSHROPRD1OPRK1 | |
| SCHEMBL13059779 | 0.78 | CYP3A4 (0.56) | HSD11B1APPTSHROPRD1OPRM1 | |
| SCHEMBL11159629 | 0.78 | APP (0.55) | APPMAPTTSHROPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | HSD11B1 3216/4885APP 3260/4885MAPT 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.